Brit received her PhD from the ETH Zurich, Switzerland, where she analysed host-pathogen interactions using the model organism Salmonella Typhimurium with a focus on the SPI-1 Type III secretion system. During her postdoctoral research at the Institute for Molecular Bioscience (UQ), Brit investigating bacterial cytokinesis and signalling focussing on histidine kinases. She then moved into Research Management and gained experience as the Scientific Manager of the Max Planck Institute for Biology of Ageing in Cologne, Germany; Policy and Grants Research Officer at Griffith University; and Research Manager at the School of Architecture at UQ before joining the StemCARE Team.

Industry Engagement and Collaborations

​​Dr Winnen has an extensive network across acadmia and industry, e.g. ETH Zurich Switzerland, Max Planck Insitutes Germany, University of Cambridge, TU and LMU Munich Germany, University of Cologne Germany, ​Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases, EIT Health e.V.​, ​Philips Research, Federal Institute for Drugs and Medical Devices Germany, Deutsches Krebsforschungs Zentrum Germany, center of advanced european studies and research​ (caesar) Bonn Germany, ​​​Roche, Novartis, Perkin Elmer, ​Evotec, Miltenyi, Molecular Partners AG​ Switzerland, Genentech​ US, UCSD, Scripps Research Institute ​US, Salk Insitute for Biological Studies US, ​​Albert Einstein College of Medicine US, Trinity College Dublin​, Massachusetts General Hospital US, Merck, Menzies Health Institute Queensland​, Takeda Pharmaceuticals International AG​, Center for Clinical Trials - ZKS Köln​ Germany​, CeMM Research Center for Molecular Medicine Austria​, Technische Universität Darmstadt Germany​, ​University of Vienna Austria, Griffith University, QUT, Curtin University​, University Hospital Zürich​ Switzerland, ​Bavarian Nordic​ Germany, Boehringer Ingelheim​, CSL Behring Switzlerland. ​ https://au.linkedin.com/in/brit-winnen-03907353​